Sareum Holdings (SAR) Price & Analysis

Compare

26 Followers

SAR Stock Chart & Stats

15.00p

0.10p(0.44%)

At close: Jan 09 4:00 PM EST

15.00p

0.10p(0.44%)

Day’s Range― - ―

52-Week Range9.50p - 29.00p

Previous CloseN/A

Volume41.80K

Average Volume (3M)619.72K

Market Cap

£22.78M

Enterprise Value17.85M

Total Cash (Recent Filing)£3.55M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-0.52

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding138,065,170

10 Day Avg. Volume1,134,615

30 Day Avg. Volume619,716

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)8.68

Price to Sales (P/S)0.00

P/FCF Ratio-7.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free balance sheet materially reduces structural financial risk and interest obligations, giving management flexibility in negotiating partnerships, timing R&D spend, and pursuing licencing deals without fixed debt servicing. This supports sustainability through funding cycles.

Kinase Inhibition R&D Platform ExpertiseDeep domain focus on kinase inhibition is a durable scientific asset: platform expertise accelerates candidate generation, improves probability of out-licensing, and attracts collaborators seeking specific modality know-how. That structural capability underpins long-term deal flow potential.

Asset-light Monetisation/licensing ModelAn asset-light revenue model centered on licensing and research collaborations lets Sareum monetise early-stage assets without building commercial infrastructure. This model preserves capital, enables scalable milestone/royalty income, and aligns incentives with long-term R&D productivity.

Bears Say

Pre-revenue And Persistent Operating LossesBeing pre-revenue with repeated operating losses means the company lacks internal earnings to fund development. Over time this limits reinvestment capacity, increases reliance on external capital, and raises execution risk for advancing programs without recurring commercial cash flow.

Sustained Cash Burn And Funding DependencePersistent negative operating and free cash flow creates structural funding dependence. Even with some recent narrowing, the company requires external financing or milestone receipts to continue operations, exposing it to dilution, timing risk, and potential interruptions in R&D progress.

Very Small Operating Team And Limited ScaleA five-person workforce constrains in-house R&D throughput, clinical development capacity, and program diversification. Long-term execution depends heavily on external collaborators and partners, raising coordination risk and potentially slowing advancement across multiple candidate programs.

Sareum Holdings News

Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings has restarted its Phase 2-enabling toxicology programme...

5d ago

Sareum Holdings Passes All Resolutions at AGM, Strengthening Governance

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings plc announced that all resolutions at its...

2M ago

Sareum Holdings Advances Pipeline and Strengthens Portfolio

Sareum Holdings ( ($GB:SAR) ) has shared an update. Sareum Holdings has made significant progress in its pipeline,...

3M ago

Sareum Holdings Announces AGM and Releases Annual Report

Sareum Holdings ( ($GB:SAR) ) has provided an update. Sareum Holdings PLC has announced its Annual General Meeting...

3M ago

Sareum Holdings Enhances Financial Advisory Team with New Joint Broker Appointment

The latest announcement is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings PLC has appointed Singer Capital...

4M ago

Sareum Holdings Reports Progress in Drug Development and Strategic Collaborations

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings PLC announced its unaudited financial results for...

4M ago

Sareum Holdings Discontinues Toxicology Study for SDC-1801 Amid Safety Concerns

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings has discontinued its 16-week GLP preclinical toxicology...

5M ago

Sareum Holdings to Announce Financial Results and Host Investor Presentation

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings PLC announced it will release its financial...

5M ago

Sareum Holdings Raises Funds Through Warrant Exercise

Sareum Holdings ( ($GB:SAR) ) just unveiled an announcement. Sareum Holdings announced the exercise of warrants for 20,200...

5M ago

Sareum Holdings Increases Share Capital Through Warrant Exercise

Sareum Holdings ( ($GB:SAR) ) just unveiled an announcement. Sareum Holdings plc announced the exercise of warrants to...

5M ago

SAR FAQ

What was Sareum Holdings PLC’s price range in the past 12 months?

Sareum Holdings PLC lowest share price was 9.50p and its highest was 29.00p in the past 12 months.

What is Sareum Holdings PLC’s market cap?

Sareum Holdings PLC’s market cap is £22.78M.

When is Sareum Holdings PLC’s upcoming earnings report date?

Sareum Holdings PLC’s upcoming earnings report date is Mar 26, 2026 which is in 32 days.

How were Sareum Holdings PLC’s earnings last quarter?

Sareum Holdings PLC released its earnings results on Oct 23, 2025. The company reported -0.024p earnings per share for the quarter, missing the consensus estimate of N/A by -0.024p.

Is Sareum Holdings PLC overvalued?

According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sareum Holdings PLC pay dividends?

Sareum Holdings PLC does not currently pay dividends.

What is Sareum Holdings PLC’s EPS estimate?

Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sareum Holdings PLC have?

Sareum Holdings PLC has 138,065,170 shares outstanding.

What happened to Sareum Holdings PLC’s price movement after its last earnings report?

Sareum Holdings PLC reported an EPS of -0.024p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 17.857%.

Which hedge fund is a major shareholder of Sareum Holdings PLC?

Currently, no hedge funds are holding shares in GB:SAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sareum Holdings PLC

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.